ICER Value Assessments Could Provide US Standard, Payers, Providers Tell HHS
Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.
You may also be interested in...
Former drug pricing advisor John O’Brien discusses next steps for Administration policies around importation and international reference pricing during a speech to the Academy of Managed Care Pharmacy.
Nearly 65% of respondents reported ICER cost effectiveness reviews are 'likely' or 'extremely likely' to function as a benchmark in price negotiations with manufacturers, according to a recent survey.
CMS using authority from previously abandoned competitive acquisition program; vendors may get ability to use formularies and apply utilization management techniques like prior authorization and step therapy.